Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TRAUMA CENTER ASSOCIATION OF AMERICA via HOLLAND & KNIGHT LLP
2011 · fourth_quarter · 4A
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in health reform law pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation HR 3144 and primary federal agency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
| CELL THERAPEUTICS INC |
| 1 |
| 2010 |
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011
Field EMS Quality, Innovation, and Cost Effectiveness Improvements Act of 2011
Client: TRAUMA CENTER ASSOCIATION OF AMERICA · Firm: HOLLAND & KNIGHT LLP
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in health reform law pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation HR 3144 and primary federal agency.
Field EMS Quality, Innovation, and Cost Effectiveness Improvements Act of 2011
Client: TRAUMA CENTER ASSOCIATION OF AMERICA · Firm: HOLLAND & KNIGHT LLP
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in health reform law pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation HR 3144 and primary federal agency.
Patient-Focused Critical Care Enhancement Act
Client: AMERICAN COLLEGE OF CHEST PHYSICIANS · Firm: HOLLAND & KNIGHT LLP
HR 1581 and S. 1020, Patient-Focused Critical Care Enhancement Act; implementation of The Family Smoking Prevention and Tobacco Control Act; implementation of HR 3590, Patient Protection and Affordable Care Act; HR 3961, Medicare Physician Payment Reform Act of 2009; H. Res. 1122 & S. Res. 432, Year of the Lung; COPD policy issues; H.R. 855, Enhancing Safety in Medicine Utilizing Advanced Simulation Technologies to Improve Outcomes Now Act of 2009.
An Act to extend expiring provisions of the USA PATRIOT Improvement and Reauthorization Act of 2005 and Intelligence Reform and Terrorism Prevention Act of 2004 until February 28, 2011.
Client: AMERICAN COLLEGE OF CHEST PHYSICIANS · Firm: HOLLAND & KNIGHT LLP
HR 1581 and S. 1020, Patient-Focused Critical Care Enhancement Act; implementation of The Family Smoking Prevention and Tobacco Control Act; implementation of HR 3590, Patient Protection and Affordable Care Act; HR 3961, Medicare Physician Payment Reform Act of 2009; H. Res. 1122 & S. Res. 432, Year of the Lung; COPD policy issues; H.R. 855, Enhancing Safety in Medicine Utilizing Advanced Simulation Technologies to Improve Outcomes Now Act of 2009.
Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010
Client: NATIONAL HEMOPHILIA FOUNDATION · Firm: HOLLAND & KNIGHT LLP
Biomedical Research; CDC Hemophilia program; HR 4846 SAFE Act
Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010
Client: NATIONAL HEMOPHILIA FOUNDATION · Firm: HOLLAND & KNIGHT LLP
Biomedical Research; CDC Hemophilia program; HR 4846 SAFE Act
Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2010
Client: NATIONAL HEMOPHILIA FOUNDATION · Firm: HOLLAND & KNIGHT LLP
Biomedical Research; CDC Hemophilia program; HR 4846 SAFE Act
Regenerative Medicine Promotion Act of 2010
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Lobby in support of HR 6173. Advocate for new/modified regulations re: aprroval of regenerative medicine products. The Regenerative Medicine Promotion Act of 2010. Met with NIST to explore collaborations re: product standards
Enhancing Safety in Medicine Utilizing Leading Advanced Simulation Technologies to Improve Outcomes Now Act of 2009
Client: AMERICAN COLLEGE OF CHEST PHYSICIANS · Firm: HOLLAND & KNIGHT LLP
HR 1581 and S. 1020, Patient-Focused Critical Care Enhancement Act; implementation of The Family Smoking Prevention and Tobacco Control Act; implementation of HR 3590, Patient Protection and Affordable Care Act; HR 3961, Medicare Physician Payment Reform Act of 2009; H. Res. 1122 & S. Res. 432, Year of the Lung; COPD policy issues; H.R. 855, Enhancing Safety in Medicine Utilizing Advanced Simulation Technologies to Improve Outcomes Now Act of 2009.
Supporting the goals and ideals of the Year of the Lung 2010.
Client: AMERICAN COLLEGE OF CHEST PHYSICIANS · Firm: HOLLAND & KNIGHT LLP
HR 1581 and S. 1020, Patient-Focused Critical Care Enhancement Act; implementation of The Family Smoking Prevention and Tobacco Control Act; implementation of HR 3590, Patient Protection and Affordable Care Act; HR 3961, Medicare Physician Payment Reform Act of 2009; H. Res. 1122 & S. Res. 432, Year of the Lung; COPD policy issues; H.R. 855, Enhancing Safety in Medicine Utilizing Advanced Simulation Technologies to Improve Outcomes Now Act of 2009.
Patient-Focused Critical Care Enhancement Act
Client: AMERICAN COLLEGE OF CHEST PHYSICIANS · Firm: HOLLAND & KNIGHT LLP
HR 1581 and S. 1020, Patient-Focused Critical Care Enhancement Act; implementation of The Family Smoking Prevention and Tobacco Control Act; implementation of HR 3590, Patient Protection and Affordable Care Act; HR 3961, Medicare Physician Payment Reform Act of 2009; H. Res. 1122 & S. Res. 432, Year of the Lung; COPD policy issues; H.R. 855, Enhancing Safety in Medicine Utilizing Advanced Simulation Technologies to Improve Outcomes Now Act of 2009.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2011
Client: NATIONAL DISEASE RESEARCH INTERCHANGE · Firm: HOLLAND & KNIGHT LLP
NIH funding for human tissue supply and rare diseases; report language for S.3686, an origianl bill making appropriations for the Department of Labor, Health and Human Services, and Education and related agencies for the fiscal year ending September 30, 2011, and for other purpsoes.
A bill supporting the goals and ideals of the Year of the Lung 2010.
Client: AMERICAN COLLEGE OF CHEST PHYSICIANS · Firm: HOLLAND & KNIGHT LLP
HR 1581 and S. 1020, Patient-Focused Critical Care Enhancement Act; implementation of The Family Smoking Prevention and Tobacco Control Act; implementation of HR 3590, Patient Protection and Affordable Care Act; HR 3961, Medicare Physician Payment Reform Act of 2009; H. Res. 1122 & S. Res. 432, Year of the Lung; COPD policy issues; H.R. 855, Enhancing Safety in Medicine Utilizing Advanced Simulation Technologies to Improve Outcomes Now Act of 2009.
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMERICAN COLLEGE OF CHEST PHYSICIANS · Firm: HOLLAND & KNIGHT LLP
HR 1581 and S. 1020, Patient-Focused Critical Care Enhancement Act; implementation of The Family Smoking Prevention and Tobacco Control Act; implementation of HR 3590, Patient Protection and Affordable Care Act; HR 3961, Medicare Physician Payment Reform Act of 2009; H. Res. 1122 & S. Res. 432, Year of the Lung; COPD policy issues; H.R. 855, Enhancing Safety in Medicine Utilizing Advanced Simulation Technologies to Improve Outcomes Now Act of 2009.
2011 · fourth_quarter · Q4
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in health reform law pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation HR 3144 and primary federal agency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GOD'S LOVE WE DELIVER via HOLLAND & KNIGHT LLP
2011 · fourth_quarter · 4T
Appropriations and nutrition health policy
Appropriations and nutrition health policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL DISEASE RESEARCH INTERCHANGE via HOLLAND & KNIGHT LLP
2011 · third_quarter · Q3
NIH plan to create NCATS and eliminate NCRR; Human tissue supply for research; S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2012 (and Senate Report 112-84 accompanying this bill).
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
TRAUMA CENTER ASSOCIATION OF AMERICA via HOLLAND & KNIGHT LLP
2011 · third_quarter · Q3
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in health reform law pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation and primary federal agency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2011 · third_quarter · Q3
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards for regenerative medicine.
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST officials on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities.
GOD'S LOVE WE DELIVER via HOLLAND & KNIGHT LLP
2011 · third_quarter · Q3
Appropriations and nutrition health policy.
Appropriations and nutrition health policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRAUMA CENTER ASSOCIATION OF AMERICA via HOLLAND & KNIGHT LLP
2011 · second_quarter · Q2
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in health reform law pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GOD'S LOVE WE DELIVER via HOLLAND & KNIGHT LLP
2011 · second_quarter · Q2
Appropriations and nutrition health policy.
Appropriations and nutrition health policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL DISEASE RESEARCH INTERCHANGE via HOLLAND & KNIGHT LLP
2011 · second_quarter · Q2
NIH plan to create NCATS and eliminate NCRR; Human tissue supply for research.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NATIONAL HEMOPHILIA FOUNDATION via HOLLAND & KNIGHT LLP
2011 · second_quarter · 2T
Biomedical Research; CDC Hemophilia program; HRSA Hemophilia Program
FY 2011 Labor, Health and Human Services, Education, and Related Agencies appropriations bills; HRSA and CDC hemophilia programs; NIH research funding
Health Insurance Access and Cost Issues; implementation of Patient Protection and Affordable Care Act.
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2011 · second_quarter · Q2
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards.
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2011 · first_quarter · Q1
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with NIST to explore collaborations re: manfacturing standards; Draft legislation to support regenerative medicine research
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
TRAUMA CENTER ASSOCIATION OF AMERICA via HOLLAND & KNIGHT LLP
2011 · first_quarter · Q1
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in health reform law pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL HEMOPHILIA FOUNDATION via HOLLAND & KNIGHT LLP
2011 · first_quarter · Q1
FY 2011 Labor, Health and Human Services, Education, and Related Agencies appropriations bills; HRSA and CDC hemophilia programs; NIH research funding
Blood and blood product safety; issues related to blood product approvals; Blood donor deferral policies, 340B Drug purchasing program and orphan drugs.
Health Issues and payment; Medicare and Medicaid Reimbursement for hemophilia services and treatments
GOD'S LOVE WE DELIVER via HOLLAND & KNIGHT LLP
2011 · first_quarter · Q1
Appropriations and nutrition health policy.
Appropriations and nutrition health policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2010 · fourth_quarter · Q4
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Lobby in support of HR 6173. Advocate for new/modified regulations re: aprroval of regenerative medicine products. The Regenerative Medicine Promotion Act of 2010. Met with NIST to explore collaborations re: product standards
NATIONAL HEMOPHILIA FOUNDATION via HOLLAND & KNIGHT LLP
2010 · fourth_quarter · Q4
Biomedical Research; CDC Hemophilia program; HR 4846 SAFE Act
FY 2011 Labor, Health and Human Services, Education, and Related Agencies appropriations bills; HRSA and CDC hemophilia programs; NIH research funding
Health Issues and payment; Medicare and Medicaid Reimbursement for hemophilia services and treatments
NATIONAL DISEASE RESEARCH INTERCHANGE via HOLLAND & KNIGHT LLP
2010 · third_quarter · 3T
NIH funding for human tissue supply and rare diseases; report language for S.3686, an origianl bill making appropriations for the Department of Labor, Health and Human Services, and Education and related agencies for the fiscal year ending September 30, 2011, and for other purpsoes.
Filing targets: SENATE
NATIONAL HEMOPHILIA FOUNDATION via HOLLAND & KNIGHT LLP
2010 · third_quarter · Q3
Biomedical Research; CDC Hemophilia program; HR 4846 SAFE Act
Health Issues and payment; Medicare and Medicaid Reimbursement for hemophilia services and treatments
Blood and blood product safety; issues related to blood product approvals; Blood donor deferral policies, 340B Drug purchasing program and orphan drugs.
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2010 · third_quarter · Q3
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
CELL THERAPEUTICS, INC. via HOLLAND & KNIGHT LLP
2010 · second_quarter · Q2
Prepare application for tax credit/grant available under Sec. 48D of IRS code.
Filing targets: Food & Drug Administration (FDA), Internal Revenue Service (IRS)
NATIONAL HEMOPHILIA FOUNDATION via HOLLAND & KNIGHT LLP
2010 · second_quarter · Q2
Health Insurance Access and Cost Issues, Health Reform legislation - Health Reform Legislation.
Health Issues and payment; Medicare and Medicaid Reimbursement for hemophilia services and treatments
Blood and blood product safety; issues related to blood product approvals; Healthcare Reform legislation-340B program and orphan drugs..
AMERICAN COLLEGE OF CHEST PHYSICIANS via HOLLAND & KNIGHT LLP
2010 · second_quarter · Q2
HR 1581 and S. 1020, Patient-Focused Critical Care Enhancement Act; implementation of The Family Smoking Prevention and Tobacco Control Act; implementation of HR 3590, Patient Protection and Affordable Care Act; HR 3961, Medicare Physician Payment Reform Act of 2009; H. Res. 1122 & S. Res. 432, Year of the Lung; COPD policy issues; H.R. 855, Enhancing Safety in Medicine Utilizing Advanced Simulation Technologies to Improve Outcomes Now Act of 2009.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL DISEASE RESEARCH INTERCHANGE via HOLLAND & KNIGHT LLP
2010 · second_quarter · 2A
NIH funding for human tissue supply and rare diseases; implementation of the Cures Acceleration network within HR . 3590, the Patient Protection and Affordable Care Act.
Filing targets: SENATE
NATIONAL DISEASE RESEARCH INTERCHANGE via HOLLAND & KNIGHT LLP
2010 · second_quarter · Q2
NIH funding for human tissue supply and rare diseases; implementation of the Cures Acceleration network within HR . 3590, the Patient Protection and Affordable Care Act.
Filing targets: SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Health Issues and payment; Medicare and Medicaid Reimbursement for hemophilia services and treatments
Blood and blood product safety; issues related to blood product approvals; Blood donor deferral policies, 340B Drug purchasing program and orphan drugs.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, White House Office
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Met with NIST officials on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities. Draft legislation to support regenerative medicine research and development.
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Biomedical Research; CDC Hemophilia program; HRSA Hemophilia Program
Health Insurance Access and Cost Issues; implementation of Patient Protection and Affordable Care Act.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, White House Office
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST on standards for reginerative medicine products.
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Health Insurance Access and Cost Issues.
Blood and blood product safety; issues related to blood product approvals; Blood donor deferral policies, 340B Drug purchasing program and orphan drugs.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Health Insurance Access and Cost Issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Draft and lobby in support of legislation that contains these provisions. Advocate for new/modified regulations re: aprroval of regenerative medicine products
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Biomedical Research; CDC Hemophilia program; HR 4846 SAFE Act
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE